Sprint Bioscience: Sells TREX1 program to Gilead - Redeye
Redeye endorses today’s news that Sprint Bioscience has sold its TREX1 program to Gilead Sciences, including an upfront of USD14m, which should ease the financial situation significantly. We provide an initial take.
ANNONS
Redeye endorses today’s news that Sprint Bioscience has sold its TREX1 program to Gilead Sciences, including an upfront of USD14m, which should ease the financial situation significantly. We provide an initial take.
